COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab

BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Díaz, Eva, Gracia-Gil, Julia, García-García, Jose Gregorio, Palao, María, Romero-Sánchez, Carlos M, Segura, Tomás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366111/
https://www.ncbi.nlm.nih.gov/pubmed/32711297
http://dx.doi.org/10.1016/j.msard.2020.102402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366111/
https://www.ncbi.nlm.nih.gov/pubmed/32711297
http://dx.doi.org/10.1016/j.msard.2020.102402

Ejemplares similares